Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.
Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, Forecast to 2030
The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
Type of Tumor Marker
• ctDNA
• cfDNA
• CTCs
• Exosomes
• Others
Application
• Diagnosis / Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring
Target Cancer Indication
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Gastric Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others
End Users
• Hospitals
• Research Institutes
• Others
Key Geographical Regions
• North America
• Europe
• Asia-Pacific
• Rest of the World
Get Latest Market Insights:
Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030
The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:
Key Players:
• Amoy Diagnostics
• DiaCarta
• HaploX Biotechnology
• NeoGenomics
• QIAGEN
• Swift Biosciences
• Sysmex Inostics
• Thermo Fisher Scientific
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Non-Invasive Cancer Screening and Diagnosis
5. Market Landscape
6. Company Profiles
7. Partnerships and Collaborations
8. Funding and Investment Analysis
9. Liquid Biopsy: Initiatives of Big Pharma Players
10. Key Acquisition Targets
11. Other Non-Invasive Cancer Diagnostics
12. Market Sizing and Opportunity Analysis
13. Survey Insights
14. Conclusion
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
Request for Customization: https://www.rootsanalysis.com/reports/279/request-customization.html

Leave a Comment

Show Buttons
Hide Buttons